Findings

What do systematic reviews say?

8 questions · 8 findings · 1 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 12.5%GRADE not reported 0 · 0%Very low 0 · 0%Low 7 · 87.5%Moderate 0 · 0%High 0 · 0%

Mycophenolate mofetil vs cyclosporin

Relapse · SSNS in children

Mycophenolate mofetil showed no clear difference in relapse at 12 months compared with cyclosporin (low certainty).

1 finding from 1 review

Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
RR 1.9 [0.66, 5.46]
2 studies · 82 participants
Low

Mycophenolate mofetil vs cyclosporin

Frequent relapses · SSNS in children

The review found no eligible studies for this question.

1 finding from 1 review

Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Mycophenolate mofetil vs cyclosporin

Annualised relapse rate · SSNS in children

1 finding from 1 review

Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 3 participants
Low

Mycophenolate mofetil vs cyclosporin

Adverse events: hypertension · SSNS in children

Mycophenolate mofetil showed no clear difference in adverse effects: hypertension compared with cyclosporin (low certainty).

1 finding from 1 review

Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
RR 0.3 [0.09, 1.07]
3 studies · 144 participants
Low

Mycophenolate mofetil vs cyclosporin

Adverse effects: hypertrichosis · SSNS in children

Mycophenolate mofetil may leads to lower adverse effects: hypertrichosis compared with cyclosporin (low certainty).

1 finding from 1 review

Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
RR 0.23 [0.1, 0.5]
3 studies · 140 participants
Low

Mycophenolate mofetil vs cyclosporin

Adverse effects: lymphopenia · SSNS in children

Mycophenolate mofetil showed no clear difference in adverse effects: lymphopenia compared with cyclosporin (low certainty).

1 finding from 1 review

Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
RR 0.64 [0.08, 4.85]
2 studies · 84 participants
Low

Mycophenolate mofetil vs cyclosporin

Adverse effects: gum hypertrophy · SSNS in children

Mycophenolate mofetil may leads to lower adverse effects: gum hypertrophy compared with cyclosporin (low certainty).

1 finding from 1 review

Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
RR 0.09 [0.02, 0.47]
3 studies · 144 participants
Low

Mycophenolate mofetil vs cyclosporin

Adverse effects: reduced GFR · SSNS in children

Mycophenolate mofetil showed no clear difference in adverse effects: reduced GFR compared with cyclosporin (low certainty).

1 finding from 1 review

Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
RR 0.33 [0.01, 7.45]
1 study · 24 participants
Low